PQ 311
311. Deputy Anne Rabbitte asked the Minister for Health the reason the combined immunotherapy treatment of ipilimumab and nivolumab is not funded as a first line treatment option for advanced renal cell carcinoma but appears to be funded for melanoma cancer; his plans to fund such a combined immunotherapy treatment; and if he will make a statement on the matter. [51099/19]
Introduced
10 December 2019
Last action
—
Status
written
Sponsors
—
Subjects
Discovery layer
Source updated
10 December 2019
Summary
311. Deputy Anne Rabbitte asked the Minister for Health the reason the combined immunotherapy treatment of ipilimumab and nivolumab is not funded as a first line treatment option for advanced renal cell carcinoma but appears to be funded for melanoma cancer; his plans to fund such a combined immunotherapy treatment; and if he will make a statement on the matter. [51099/19]
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
No timeline events have been ingested for this record yet.
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
1 official file
Medicinal Products Reimbursement
Medicinal Products Reimbursement
xml · EN · 10 December 2019
Sponsors
No sponsors or actors listed by the source.
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://www.oireachtas.ie/en/debates/question/2019-12-10/311/
- Open data entity: https://data.oireachtas.ie/ie/oireachtas/question/2019-12-10/pq_311